- Home
- ISRL vs AGEN Comparison
ISRL vs AGEN Comparison
Compare ISRL & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- AGEN
- Stock Information
- Founded
- ISRL 2021
- AGEN 1994
- Country
- ISRL United States
- AGEN United States
- Employees
- ISRL N/A
- AGEN N/A
- Industry
- ISRL Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRL Finance
- AGEN Health Care
- Exchange
- ISRL Nasdaq
- AGEN Nasdaq
- Market Cap
- ISRL 80.7M
- AGEN 87.7M
- IPO Year
- ISRL 2023
- AGEN 2000
- Fundamental
- Price
- ISRL $12.55
- AGEN $6.35
- Analyst Decision
- ISRL
- AGEN Strong Buy
- Analyst Count
- ISRL 0
- AGEN 3
- Target Price
- ISRL N/A
- AGEN $16.33
- AVG Volume (30 Days)
- ISRL 4.5K
- AGEN 1.4M
- Earning Date
- ISRL 01-01-0001
- AGEN 08-07-2025
- Dividend Yield
- ISRL N/A
- AGEN N/A
- EPS Growth
- ISRL N/A
- AGEN N/A
- EPS
- ISRL 0.20
- AGEN N/A
- Revenue
- ISRL N/A
- AGEN $99,524,000.00
- Revenue This Year
- ISRL N/A
- AGEN $25.31
- Revenue Next Year
- ISRL N/A
- AGEN N/A
- P/E Ratio
- ISRL $63.10
- AGEN N/A
- Revenue Growth
- ISRL N/A
- AGEN N/A
- 52 Week Low
- ISRL $11.08
- AGEN $1.38
- 52 Week High
- ISRL $14.00
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ISRL 48.60
- AGEN 58.22
- Support Level
- ISRL $12.41
- AGEN $5.81
- Resistance Level
- ISRL $12.99
- AGEN $6.96
- Average True Range (ATR)
- ISRL 0.18
- AGEN 0.62
- MACD
- ISRL 0.01
- AGEN -0.06
- Stochastic Oscillator
- ISRL 77.61
- AGEN 60.08
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).